Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UroGen Pharma (URGN) EBITDA (2017 - 2025)

UroGen Pharma's EBITDA history spans 9 years, with the latest figure at -$26.4 million for Q4 2025.

  • For Q4 2025, EBITDA rose 30.04% year-over-year to -$26.4 million; the TTM value through Dec 2025 reached -$153.5 million, down 21.05%, while the annual FY2025 figure was -$153.5 million, 21.05% down from the prior year.
  • EBITDA reached -$26.4 million in Q4 2025 per URGN's latest filing, up from -$33.3 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$21.9 million in Q3 2023 to a low of -$49.9 million in Q2 2025.
  • Average EBITDA over 5 years is -$30.2 million, with a median of -$28.5 million recorded in 2021.
  • Peak YoY movement for EBITDA: soared 30.97% in 2021, then tumbled 49.56% in 2025.
  • A 5-year view of EBITDA shows it stood at -$28.5 million in 2021, then decreased by 1.19% to -$28.8 million in 2022, then rose by 10.24% to -$25.9 million in 2023, then crashed by 45.7% to -$37.7 million in 2024, then soared by 30.04% to -$26.4 million in 2025.
  • Per Business Quant, the three most recent readings for URGN's EBITDA are -$26.4 million (Q4 2025), -$33.3 million (Q3 2025), and -$49.9 million (Q2 2025).